Arganova Multidose
Arganova Multidose Uses, Dosage, Side Effects, Food Interaction and all others data.
Arganova Multidose is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Arganova Multidose is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Arganova Multidose is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Arganova Multidose is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Arganova Multidose does not require the co-factor antithrombin III for antithrombotic activity. Arganova Multidose exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Arganova Multidose is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Arganova Multidose has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein).Arganova Multidose is capable of inhibiting the action of both free and clot-associated thrombin.
Trade Name | Arganova Multidose |
Availability | Prescription only |
Generic | Argatroban |
Argatroban Other Names | Argatroban |
Related Drugs | warfarin, Coumadin, heparin, alteplase, Jantoven, streptokinase |
Type | |
Formula | C23H36N6O5S |
Weight | Average: 508.64 Monoisotopic: 508.246789457 |
Protein binding | 54% |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | Netherlands |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Arganova Multidose is a synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use.
Arganova Multidose is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
Arganova Multidose is also used to associated treatment for these conditions: Thrombotic events
How Arganova Multidose works
Arganova Multidose exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.
Toxicity
Excessive bleeding
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
- Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of argatroban; however, the evidence is conflicting.
- Exercise caution with St. John's Wort.
Arganova Multidose Drug Interaction
Major: enoxaparin, enoxaparin, clopidogrel, clopidogrelUnknown: lorazepam, lorazepam, amoxicillin / clavulanate, amoxicillin / clavulanate, bumetanide, bumetanide, diltiazem, diltiazem, propofol, propofol, furosemide, furosemide, levofloxacin, levofloxacin, octreotide, octreotide
Arganova Multidose Disease Interaction
Volume of Distribution
- 174 mL/kg
- 12.18 L [70-kg adult]
Elimination Route
Bioavailability is 100% (intravenous).
Half Life
39 and 51 minutes
Clearance
- 5.1 L/kg/hr [infusion doses up to 40 mcg/kg/min]
Elimination Route
Arganova Multidose is excreted primarily in the feces (65%), presumably through biliary secretion; 22% is eliminated via urine.
Innovators Monograph
You find simplified version here Arganova Multidose